<DOC>
	<DOCNO>NCT00910897</DOCNO>
	<brief_summary>Primary objective : - Compare complete remission ( CR ) rate ( i.e. , true CR , negative immunofixation ) achieve either four course VD four course VTD . Secondary objective : - Compare follow parameter follow 4 cycle VD VTD induction treatment : - CR rate+ good partial remission ( VGPR ) rate - Overall remission rate ( CR + VGPR + partial remission ( PR ) rate ) - K/l light chain ratio patient CR . - Safety ( quality sample stem cell , extrahaematological haematological toxicity : specially neurological toxicity , length hospitalization ) . - Compare CR rate CR + VGPR rate post-induction autologous stem cell transplantation ( ASCT ) .</brief_summary>
	<brief_title>Study Myeloma Patients Newly Diagnosed Treated Induction With Velcade-Dex Velcade ( Bortezomib ) Thalidomide Dexamethasone ( VTD )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Newly diagnose symptomatic multiple myeloma ( MM ) patient Aged 65 Candidate ASCT , measurable level paraprotein serum ( ³ 10 g/L ) urine ( ³ 200 mg/day ) Using effective contraceptive method ( fertile men , woman childbearing potential ) Provision inform consent No evidence active infection Asymptomatic MM Nonsecretory MM Aged 66 year ECOG performance status 2 ( see Appendix 2 ) Proven amyloidosis A personal medical history cancer ( except basocellular skin cancer situ cervical cancer ) Positive HIV serology A personal medical history severe psychiatric disease Severe diabetes contraindicate use highdose dexamethasone NCI grade ³ 2 peripheral neuropathy Serum clinical chemistry : creatinine level &gt; 300 µmol/L require dialysis bilirubin , transaminases GamaGT &gt; 3 upper normal limit ( UNL ) Prior current systemic therapy MM , include steroid ( except emergency use 4day block dexamethasone screen phase randomization ) Radiation therapy 2 week precede randomization A personal medical history allergic reaction compound contain boron mannitol Noncontrolled severe cardiovascular disease ( include myocardial infarction 6 month prior recruitment ) NYHA class III IV renal failure Use investigational drug 30 day precede randomization Pregnant lactate woman ; serum BetahCG pregnancy test must perform screen phase female patient childbearing potential Severe pulmonary trouble ( include acute infiltrative pneumopathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Newly Diagnosed</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>induction</keyword>
	<keyword>Thalidomide</keyword>
</DOC>